NSE filing, NSE: ACCPL. Summary written from the filing by ALFA Finder's alert engine.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹181.00
- Market cap
- ₹201.2 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 20.8×Sector 46.1×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited held its 3rd Annual General Meeting on August 27, 2026. The meeting transacted business including the adoption of financial statements and director re-appointment.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited has provided the web link for shareholders to access its Annual Report for FY 2025-26 and the 3rd AGM notice.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited has scheduled its 3rd Annual General Meeting for August 27, 2026, to be conducted through video conferencing for ordinary business transactions.
Other other announcement announcements
All →Spice Islands Industries Other Announcement
Spice Islands Industries filed a Reg 32 statement reporting no deviation in preferential issue fund utilization for Q3 FY27. The ₹8.70 Crore raise is fully deployed.
Setubandhan Infrastructure Other Announcement
RP informs exchanges that Setubandhan Infrastructure cannot file quarterly compliance documents due to depository fee non-payment. The company remains under CIRP with a pending NCLAT appeal.
Man Infraconstruction Other Announcement
Man Infraconstruction filed a Reg 32 quarterly statement confirming no deviation in use of preferential-warrant proceeds. No deviation or variation arose for the quarter ended September 30, 2026.
Black Buck Other Announcement
BlackBuck's ICRA monitoring agency report for Q1 FY27 confirms IPO proceeds utilization remains in line with stated objects. No deviation was observed in the quarter.
Raama Finance Other Announcement
Raama Finance appointed M/s. Kumar Gaurav & Co. as statutory auditor for three months effective October 29, 2026. The routine appointment carries no financial impact.
Teja Engineering Industries Other Announcement
Teja Engineering Industries filed a non-applicability certificate for Reg 27(2) Corporate Governance for Q1 FY27. As an NSE Emerge-listed SME, the company is exempt from this periodic disclosure.